Data coverage, completeness and provenance for RECCE PHARMACEUTICALS LTD in the Stock Market API — Health Care · Biotechnology.
Source date: 2026-10-30T05:10:11. Source: yfinance. Collection time is shown separately and does not establish a trade date.
| Date | Close | Currency | Source | Adjustment basis |
|---|---|---|---|---|
| 2026-10-30 | 0.3600 | AUD | yfinance | Split- and dividend-adjusted close |
| 2026-10-29 | 0.3300 | AUD | yfinance | Split- and dividend-adjusted close |
| 2026-10-28 | 0.3150 | AUD | yfinance | Split- and dividend-adjusted close |
| 2026-10-27 | 0.3100 | AUD | yfinance | Split- and dividend-adjusted close |
| 2026-10-26 | 0.3250 | AUD | yfinance | Split- and dividend-adjusted close |
GET /api/v1/companies/RCE/prices · Price parameters and adjustment semantics
Recce Pharmaceuticals Ltd, discovers, develops, and commercializes synthetic antiinfectives in Australia, the United Kingdom, and the United States. The company's lead candidate is RECCE 327 (R327) for the treatment of life-threatening bacterial infections. In addition, its product pipeline comprises R327 Intravenous, which is in Phase I and Phase I/II clinical trial for the treatment of urinary tract infections/urosepsis; and R327 Topical Gel, which is in Phase II clinical trial for the treatment of acute bacterial skin and skin structure infections, as well as is in Phase III clinical trials for topical wound infections and diabetic foot infections. The company has strategic partnership with Murdoch Children's Research Institute for development of the Acinetobacter baumannii; and cooperative research and development agreement with the United States Army Medical Research Institute of Infectious Diseases (USAMRIID) to be tested against highly hazardous pathogens. The company was formerly known as Recce Limited and changed its name to Recce Pharmaceuticals Ltd in November 2017. Recce Pharmaceuticals Ltd was incorporated in 2007 and is headquartered in Sydney, Australia.
Website: https://www.recce.com.au · Profile fields populated: 60%
Share of stored fields populated in the anchor reporting period (FY2026), primary source yfinance. Full per-field breakdown: GET /api/v1/companies/RCE/financials.
Stored values for the most recent fiscal-year periods, with per-period field counts and the primary source each period came from. Values are shown at reported scale without interpretation.
| Period | Period end | Revenue | Net income | Total assets | Total equity | Fields populated | Source |
|---|---|---|---|---|---|---|---|
| FY2026 (AUD) | 2026-06-30 | 25 | yfinance | ||||
| FY2025 (AUD) | 2025-06-30 | 25 | yfinance | ||||
| FY2024 (AUD) | 2024-06-30 | 25 | yfinance | ||||
| FY2023 (AUD) | 2023-06-30 | 25 | yfinance |
The endpoints below describe available datasets for this listing. Missing fields remain unknown. Free API keys — no card required.
Name, sector, industry, HQ, employees, market cap, source-tagged.
GET /api/v1/companies/RCE
Multi-year statements with per-field source tags and completeness.
GET /api/v1/companies/RCE/financials
P/E, P/B, ROE, ROA, margins, EPS, debt/equity — formulas documented.
GET /api/v1/companies/RCE/metrics/summary
Report PDFs with LLM-ready markdown conversions where available.
GET /api/v1/companies/RCE/filings
Dated press releases and announcements with source links.
GET /api/v1/companies/RCE/news
Create a free key, then:
curl -H "X-API-Key: KEY" https://stockmarketapi.ai/api/v1/companies/RCE
Free tier — instant API key. Built for AI agents.